Prominent IP Updates on Feb 05, 2015

Pfizer to Buy Hospira for $15 Billion as Drug Maker Looks to Expand Revenue

Pfizer has agreed to acquire Hospira, a big maker of injectable drugs, for $15.2 billion. The acquisition is the first major deal for Pfizer since last year’s failed attempt to buy AstraZeneca for more than $100 billion.

Veeam claims victory in Symantec patent battle

Veeam has claimed victory over Symantec as the latter’s lawsuit over backup patents unravels. Symantec had started legal action against its backup rival in 2012, claiming Veeam infringed four separate patents.

Orexo commences patent infringement litigation against Actavis concerning Abstral® in the US

Orexo AB, today announced that it has filed a patent infringement action in United States District Court for the District of New Jersey, against Actavis Laboratories FL, Inc., Andrx Corporation, Actavis, Inc. and Actavis Pharma, Inc.

Horizon Pharma gets VIMOVO related patent with protection to 2031 from USPTO

Horizon Pharma has announced the issuance of a patent from the USPTO titled ‘Method for Treating a Patient at Risk for Developing an NSAID-associated Ulcer’ that relates to the use of VIMOVO® (naproxen/esomeprazole magnesium) in patients taking low dose aspirin.

Ryan Seacrest-backed smartphone keyboard Typo fined $860K in BlackBerry patent spat

A U.S. judge had ordered a company partly financed by Ryan Seacrest to pay $860,600 in fines for ignoring a previous court order to stop selling a device that attaches to an iPhone to give it a keyboard similar to a BlackBerry.

ARCA biopharma Announces Patent Issuance for Methods and Compositions of S-isomer Formulation of Gencaro

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the USPTO has issued a patent on methods and compositions of the S-isomer formulation of GencaroTM (bucindolol hydrochloride).

ProLynx Issued Key Patent For Using Releasable Linkers On Insoluble Carriers

ProLynx LLC, a biotechnology company – today announced that the USPTO has issued US Patent 8,946,405 titled “Controlled Release from Solid Supports.” The patent broadly covers the controlled release of drugs or pro-drugs using ProLynx’s beta-eliminative linkers on insoluble carriers.

Marathon Patent Group Secures $50 Million Long Term Financing

Marathon Patent Group, Inc., a patent licensing company, announced today that it has entered into a $50 million long term financing facility with funds managed by affiliates of Fortress Investment Group

8×8 Issued New Communications Patent by U.S. Patent and Trademark Office

8×8, Inc., a leading provider of cloud-based unified communications and contact center solutions, today announced that it has been awarded a new patent related to its communication technologies.

Oxis Biotech Inc. Provides Update for P62-ZZ Multiple Myeloma Patent Application

Oxis International, Inc. a biotechnology company focused on cannabinoid therapy development and commercialization, provided today an update on its P62-ZZ Chemical Inhibitor and Therapeutic Potential for Multiple Myeloma patent application for shareholders and other interested parties.

TeleCommunication Systems Adds 13 U.S. Patents Advancing Public Safety, Location-Based Services, Messaging and Secure Communications

TeleCommunication Systems, Inc., a world leader in highly reliable and secure wireless communication technology, today announced that the USPTO issued TCS 13 U.S. patents during the fourth quarter of 2014

Corning glass museum wins patent for electric hot shop

The Corning Museum of Glass and Spiral Arts, a Seattle-based manufacturer and distributor for glass furnaces and tools, were awarded a patent for the electric glass hot shop system.

iBio, Inc. (IBIO) Receives New U.S. Patent for iBioModulator Protein Portfolio

iBio, Inc. announced the issue of a new U.S. patent in the company’s iBioModulator” thermostable immunomodulator protein portfolio.

Futura Medical gets US patent extension

The US Patent & Trademark Office has granted a three-year extension to the patent protection of MED2002, Futura Medical novel topical gel for the treatment of erectile dysfunction (ED).

Ecosphere Technologies Receives Two New U.S. Patents for Its Patented Ozonix(R) Technology

Ecosphere Technologies, Inc., a technology development and intellectual property licensing company, today announced that two Ozonix® patents have been approved by the USPTO, bringing Ecosphere’s Ozonix® intellectual property portfolio to 9 approved U.S. patents with an additional 12+ patents pending.

Merck Sales Fall on Stronger Dollar, Patent Expirations

Merck and Co.’s fourth-quarter sales declined on a stronger U.S. dollar and patent expirations for top drugs, while a weaker-than-expected 2015 outlook and new concerns over prospects for an experimental hepatitis C treatment weighed on Merck shares.